|Articles|October 14, 2019
Quantifying Quality Attributes of AAV Gene Therapy Vectors by SEC-UV-MALS-dRI
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
Cellares Extends Cell Therapy Automation Beyond T Cell Therapies
3
Containment to Protection: Packaging Trends Impacting Biopharma
4
FDA Clears Affinia’s AFTX-201 for Phase I/II BAG3 Cardiomyopathy Trial
5